Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001450000 | SCV001653550 | uncertain significance | Malignant hyperthermia, susceptibility to, 1 | 2023-04-06 | reviewed by expert panel | curation | This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of arginine with histidine at codon 3348 of the RYR1 protein, p.(Arg3348His). This variant has been reported in two unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, both of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4_Supporting (PMID:15731587, PMID:25735680). No functional studies were identified for this variant. A REVEL score of 0.705 supports neither a pathogenic nor a benign status for this variant. This variant has been classified as a Variant of Unknown Significance. Criteria implemented: PS4_Supporting. |
Fulgent Genetics, |
RCV002492407 | SCV002796417 | uncertain significance | Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion; King Denborough syndrome | 2022-03-03 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000119399 | SCV003813034 | uncertain significance | not provided | 2022-01-16 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV001450000 | SCV004820965 | uncertain significance | Malignant hyperthermia, susceptibility to, 1 | 2023-09-17 | criteria provided, single submitter | clinical testing | This missense variant replaces arginine with histidine at codon 3348 of the RYR1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in two individuals affected with malignant hyperthermia, including one who also carried additional VUS RYR1 co-variants (PMID: 15731587, 25735680). This variant has been identified in 5/282378 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Leiden Muscular Dystrophy |
RCV000119399 | SCV000154306 | not provided | not provided | no assertion provided | not provided | ||
Genome Diagnostics Laboratory, |
RCV000119399 | SCV001808316 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000119399 | SCV001951165 | uncertain significance | not provided | no assertion criteria provided | clinical testing |